NASDAQ$JBIO
Jade Biosciences Inc · Q2 2024 earnings
Q2 2024 earnings · · After market close · Investor relations
Briefing
Jade Biosciences Inc reported its financial results for the second quarter ended June 30, 2026, with increased operating expenses driven by clinical development activities.
The company recorded no revenue and a net loss of $55.8 million for the quarter. Research and development expenses rose to $50.1 million, reflecting ongoing advancement of JADE101 and other pipeline programs. Cash and investments totaled $461.2 million, providing runway for planned clinical milestones.
- Net loss widened to $55.8 million from $32.1 million in the prior-year quarter due to higher R&D spend.
- R&D expenses reached $50.1 million, including $13.0 million in related-party costs tied to Paragon collaborations.
- Cash and cash equivalents stood at $107.3 million with $354.0 million in investments at quarter end.
- Positive interim Phase 1 data for JADE101 announced, supporting advancement into Phase 2 in IgAN patients.
Headline financials
Revenue & EPS history
Aerovate · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-1.6%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+2.6%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+24.6%
Q3 2023
Best reaction
-35.0%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | +1.2% | +1.0% | +11.6% | |
| Q2 2025 | +0.1% | -0.5% | +4.9% | |
| Q1 2025 | +1.8% | -0.3% | -4.8% | |
| Q4 2024 | +0.4% | +0.4% | -85.8% | |
| Q3 2024 | +0.0% | -3.8% | -2.7% | |
| Q1 2024 | -2.8% | +3.7% | +16.1% | |
| Q4 2023 | -0.5% | +14.7% | -17.8% | |
| Q3 2023 | +24.6% | +27.6% | +68.5% | |
| Q2 2023 | -3.5% | -6.0% | -10.8% | |
| Q1 2023 | -7.6% | -12.2% | -19.8% | |
| Q4 2022 | +0.7% | +1.7% | +9.4% | |
| Q3 2022 | +0.6% | -7.1% | +32.9% | |
| Q2 2022 | -13.7% | -17.3% | -26.4% | |
| Q1 2022 | -6.3% | +0.7% | -5.9% | |
| Q4 2021 | +8.0% | -4.8% | -24.9% | |
| Q3 2021 | -35.0% | -33.8% | -42.7% | |
| Q2 2021 | +1.8% | -1.0% | +72.5% | |
| Q1 2021 | +1.8% | -1.0% | +72.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro